Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.25, Iss.10, 2009-10, pp. : 23-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer

By Bajetta E.

Drugs & Aging, Vol. 15, Iss. 4, 1999-10 ,pp. : 271-283

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Aromatase Inhibitors Evolution as Potential Class of Drugs in the Treatment of Postmenopausal Breast Cancer Women

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 7, 2018-03 ,pp. : 609-621

Bentham Science Publishers

Access to resources Recommend Favorite

Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 6, 2008-06 ,pp. : 564-574

Bentham Science Publishers

Access to resources Recommend Favorite

Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

By Rieber Alyssa G. Theriault Richard L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 3, 2005-05 ,pp. : 309-314

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite